Faculty Opinions recommendation of Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results.

AbstractPolypoidal choroidal vasculopathy (PCV) is a vision-threatening disease common in Asian populations. However, the optimal treatment for PCV remains under debate. We searched the databases with optimal searching strategy. The study included randomized clinical trials and prospective studies that recruited patients with active PCV who had received interventions, including PDT, anti-VEGF, or a combination of PDT and anti-VEGF. The Grading of Recommendations Assessment, Development, and Evaluation methodology was used for rating the quality of evidence. Our study included 11 studies involving 1277 patients. The network meta-analysis of RCTs revealed the anti-VEGF group, early combination group, and late combination group had significant BCVA changes compared with the PDT group. Early combination therapy led to a significant decrease in CRT compared with PDT, anti-VEGF, and late combination therapy. Additionally, the early combination group had a significantly higher complete polyp regression rate than the anti-VEGF group. No significant differences were detected in the analysis of the number of anti-VEGF injections and safety profile. This network meta-analysis revealed that early combination therapy exhibited better efficacy related to anatomical outcomes than other therapies. Nonetheless, no significant differences related to BCVA change could be detected between anti-VEGF and late combination therapy.

Download Full-text

Replacement of polyps with type 1 macular neovascularization in polypoidal choroidal vasculopathy imaged with swept source OCT angiography

American Journal of Ophthalmology Case Reports ◽

10.1016/j.ajoc.2021.101057 ◽

2021 ◽

Vol 22 ◽

pp. 101057

Author(s):

Mengxi Shen ◽

Qiyu Bo ◽

Minlu Song ◽

Xiaoshuang Jiang ◽

Zohar Yehoshua ◽

...

Keyword(s):

Polypoidal Choroidal Vasculopathy ◽

Oct Angiography ◽

Swept Source ◽

Swept Source Oct ◽

Swept Source Oct Angiography ◽

Choroidal Vasculopathy

Download Full-text

Bevacizumab for serous changes originating from a persistent branching vascular network following photodynamic therapy for polypoidal choroidal vasculopathy

Japanese Journal of Ophthalmology ◽

10.1007/s10384-011-0045-z ◽

2011 ◽

Vol 55 (4) ◽

pp. 370-377 ◽

Cited By ~ 14

Author(s):

Kyu Seop Kim ◽

Won Ki Lee

Keyword(s):

Photodynamic Therapy ◽

Polypoidal Choroidal Vasculopathy ◽

Vascular Network ◽

Branching Vascular Network ◽

Choroidal Vasculopathy

Download Full-text

One-year outcomes of fixed-dosing Aflibercept therapy for pre treated and naive polypoidal choroidal vasculopathy patient

BMC Ophthalmology ◽

10.1186/s12886-021-01829-2 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Hun Gu Choo ◽

Jin Hae Lee ◽

Hyun Sub Oh ◽

Soon Hyun Kim ◽

Yong Sung You ◽

...

Keyword(s):

Polypoidal Choroidal Vasculopathy ◽

Vision Loss ◽

Case Series ◽

Age Related Macular Degeneration ◽

Research Information ◽

Age Related ◽

Case Series Study ◽

Treatment Naïve ◽

One Year ◽

Choroidal Vasculopathy

Abstract Background Polypoidal choroidal vasculopathy (PCV) is a type of age-related macular degeneration that can cause permanent vision loss. The purpose of this paper was to report the one-year outcomes of fixed-dosing aflibercept therapy for the treatment of PCV. Methods This was a prospective, single-arm, interventional case series study of 25 PCV patients; 12 pre-treated and 13 treatment-naïve patients. The patients were treated and monitored for 12 months. Each patient was administered with an aflibercept (2.0 mg) injection every month for the first 3 months (the loading phase), and thereafter, once every 2 months. At every follow-up visit, best-corrected visual acuity (BCVA) test, fundus examination, and optical coherence tomography for measuring the central subfield macular thickness (CSMT) were performed. Fluorescein and indocyanine green angiography were conducted at baseline and at 4 and 12 months. Results After 12 months of aflibercept therapy, the mean BCVA of the patients significantly improved from 65.48 letters at baseline to 69.91 letters (p=0.001), and the CSMT significantly decreased from 406.92 um at baseline to 276.12 um (p< 0.001). Additionally, ten patients (40%) showed complete polyp regression. The treatment-naïve patients showed a statistically significant improvement in BCVA from 66.58 letters at baseline to 76.36 letters at 12 months, and a significant decrease in CSMT, from 462 to 243 um. In the pre-treated group, there was no change in BCVA (64.46 letters), and the decrease in CSMT from 356.08 to 303.69 um was not statistically significant. Conclusions The fixed-dosing aflibercept regimen is effective for treating patients with PCV and is more effective in treatment-naïve patients than in pre-treated patients. Trial registration Clinical Research Information Service (CRiS), Republic of Korea. Identifer: KCT0005798, Registered: Jan 20, 2021. Retrospectively registered, URL: https://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=18546

Download Full-text

The implications of subretinal fluid in pachychoroid neovasculopathy

Scientific Reports ◽

10.1038/s41598-021-83650-x ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Geun Woo Lee ◽

Hyeon Cheol Roh ◽

Se Woong Kang ◽

A. Young Kim ◽

Hoon Noh ◽

...

Keyword(s):

Central Serous Chorioretinopathy ◽

Polypoidal Choroidal Vasculopathy ◽

Multimodal Imaging ◽

Optical Coherence Tomography Angiography ◽

Subretinal Fluid ◽

Longitudinal Changes ◽

History Of ◽

Pachychoroid Neovasculopathy ◽

Choroidal Vasculopathy ◽

Epidemiological Parameters

AbstractThis study aimed to identify the clinical characteristics and longitudinal changes in exudative pachychoroid neovasculopathy (PNV) and non-exudative PNV. This retrospective cohort study involved 81 eyes of PNV diagnosed by multimodal imaging including optical coherence tomography angiography. At baseline, they were divided into exudative PNV group and non-exudative PNV group depending on the presence of subretinal fluid. The clinical features of both groups and the longitudinal changes were investigated and compared. There were 55 eyes with non-exudative PNV and 26 eyes with exudative PNV. Individuals with non-exudative PNV were older, more frequently asymptomatic and had a higher prevalence of polypoidal choroidal vasculopathy in the opposite eye (all P’s < 0.05). Whereas individuals with exudative PNV showed thicker choroid and more frequent history of central serous chorioretinopathy (all P’s < 0.001). During about 12 months of longitudinal observation, the transformation into polypoidal choroidal vasculopathy was noted in 4 eyes of non-exudative PNV group, whereas in none of the exudative PNV group. Exudative PNV and non-exudative PNV seem to be separate entities with different epidemiological parameters. Non-exudative PNV, which is frequently found without symptoms at an older age, is suspected to be the significant precursor lesion of polypoidal choroidal vasculopathy. In contrast, exudative PNV may share the same pathophysiology as central serous chorioretinopathy.

Download Full-text